On June 19, 2019 Seven and Eight Biopharmaceuticals Inc. reported that it has signed a clinical research collaboration agreement with Roche to explore the combination of Seven and Eight’s BDB001, an immune modulator targeting toll-like receptors (TLR) 7 and 8, and atezolizumab, a monoclonal antibody against the checkpoint target of PD-L1, in treating solid tumors (Press release, Seven and Eight Biopharmaceuticals, JUN 19, 2019, View Source [SID1234537175]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to enter into clinical collaboration with Roche," says Dr. Walter Lau, CEO of Seven and Eight. "Toll-like receptors 7 and 8 are amongst the most promising targets for immuno-oncology, and our dual agonists have demonstrated the ability to stimulate specific types of innate immune responses, generating enhanced adaptive anti-tumor immunity. We hope through our joint efforts with Roche, we can better delineate how to use BDB001 and atezolizumab together in the treatment of cancer patients."

Under the terms of the agreement, Seven and Eight will sponsor and be responsible for the conduct of the clinical study, in which the combined regimen of BDB001 and atezolizumab is studied for safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activities in solid tumor patients.